Form 4: CEO Turtle Sells Spyre Therapeutics Shares

Spyre Therapeutics CEO Cameron Turtle has sold a significant number of company shares through a pre-arranged trading plan.

Summary

• Cameron Turtle, CEO of Spyre Therapeutics, Inc. (SYRE), reported the sale of common stock on July 1, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025.
• A total of 10,176 shares were sold at a weighted average price of $87.44, with individual sales ranging from $86.82 to $87.81.
• An additional 4,234 shares were sold at a weighted average price of $88.12, with prices ranging from $87.82 to $88.75.
• Furthermore, 590 shares were sold at a weighted average price of $88.91, with prices ranging from $88.86 to $88.98.
• Following these transactions, Mr. Turtle beneficially owns 582,540 shares of common stock.
• This ownership includes 72,623 shares that vest monthly through November 2026, contingent on continued service.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the volume of shares sold by the CEO, despite the use of a Rule 10b5-1 plan.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive transactions.
• The CEO continues to hold a substantial number of shares (582,540) after the reported sales.
• A portion of the CEO's holdings (72,623 shares) are subject to vesting, aligning future incentives with continued employment.

Negatives

• The CEO has sold a notable number of shares, which could be perceived negatively by the market.
• The total value of shares sold is substantial, although specific aggregate figures are not provided in this filing.

Risks

• Potential for negative market perception due to insider selling, even if executed under a pre-planned trading strategy.
• Future vesting of shares is contingent on continued service, introducing a risk of forfeiture if the reporting person departs.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider selling, particularly by CEOs, is a common event. The use of a Rule 10b5-1 plan is a standard practice to mitigate concerns about timing and potential insider trading allegations, allowing executives to diversify holdings or meet financial obligations in a structured manner.

Stakeholder Impact

• Shareholders: May interpret the CEO's sales as a lack of confidence in future stock performance, potentially impacting share price, although the Rule 10b5-1 plan mitigates this concern to some extent.
• Employees: May also view the sales with concern, potentially affecting morale if they perceive it as a negative signal.
• Management: The CEO's continued beneficial ownership and vesting schedule suggest ongoing commitment to the company.

Next Steps

• The reporting person may continue to sell shares according to the Rule 10b5-1 plan.
• The company may provide further information upon request from the SEC or security holders regarding the specific sale prices.

Key Dates

Recommendation

The sale of shares by the CEO, even under a Rule 10b5-1 plan, warrants attention. However, the continued substantial ownership and the structured nature of the sale suggest it may be for personal financial planning rather than a negative outlook on the company's prospects. Without further context on the company's performance or future catalysts, a 'hold' recommendation is prudent.

Keywords

Insider Trading, Stock Sale, Rule 10b5-1, CEO, Spyre Therapeutics, SYRE, Beneficial Ownership, Common Stock, Vesting Shares